Blue Trust Inc. Acquires 197 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Blue Trust Inc. increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,056 shares of the medical research company’s stock after acquiring an additional 197 shares during the quarter. Blue Trust Inc.’s holdings in Bio-Rad Laboratories were worth $353,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BIO. UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after purchasing an additional 45 shares during the period. Wahed Invest LLC raised its holdings in Bio-Rad Laboratories by 14.0% in the 1st quarter. Wahed Invest LLC now owns 399 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 49 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Bio-Rad Laboratories by 7.7% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company’s stock worth $289,000 after acquiring an additional 60 shares during the period. Capital Advisors Ltd. LLC grew its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares in the last quarter. Finally, Natixis increased its position in shares of Bio-Rad Laboratories by 3.4% during the first quarter. Natixis now owns 1,986 shares of the medical research company’s stock valued at $687,000 after purchasing an additional 65 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Citigroup upgraded shares of Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $350.00 to $400.00 in a research note on Tuesday, October 1st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Finally, StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $368.20.

Insider Transactions at Bio-Rad Laboratories

In related news, EVP James Barry sold 623 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now owns 147 shares in the company, valued at $48,582.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Price Performance

NYSE:BIO opened at $335.21 on Thursday. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. The firm has a market cap of $9.56 billion, a PE ratio of -32.36 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 12 month low of $261.59 and a 12 month high of $364.24. The company’s 50-day moving average price is $331.15 and its two-hundred day moving average price is $307.25.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, topping the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business had revenue of $638.50 million for the quarter, compared to the consensus estimate of $645.79 million. During the same period in the previous year, the business earned $3.00 EPS. Bio-Rad Laboratories’s revenue was down 6.3% compared to the same quarter last year. On average, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.